UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000006599 |
|---|---|
| Receipt number | R000007736 |
| Scientific Title | Evaluation of effect of cilostazol on cerebral glucose metabolism in patients with amnestic mild cognitive impairment and preclinical Alzheimer's disease with lacunar infarction. |
| Date of disclosure of the study information | 2011/10/25 |
| Last modified on | 2014/10/24 09:43:19 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Evaluation of effect of cilostazol on cerebral glucose metabolism in patients with amnestic mild cognitive impairment and preclinical Alzheimer's disease with lacunar infarction.
Acronym
Effect of cilostazol on cerebral glucose metabolism in preclinical Alzheimer's disease
Scientific Title
Evaluation of effect of cilostazol on cerebral glucose metabolism in patients with amnestic mild cognitive impairment and preclinical Alzheimer's disease with lacunar infarction.
Scientific Title:Acronym
Effect of cilostazol on cerebral glucose metabolism in preclinical Alzheimer's disease
Region
| Japan |
Condition
Condition
amnestic mild cognitive impairment and preclinical Alzheimer's disease
Classification by specialty
| Neurology | Geriatrics | Psychiatry |
| Radiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
evaluation of effect monotherapy of cilostazol on cognitive function and cerebral glucose metabolism
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
MMSE,WMS-R,FDG-PET
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Cilostazol 100mg daily for 3 months
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
MMSE 24-30
Key exclusion criteria
other anti-dementia drugs
Target sample size
10
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tsuneyoshi Ota |
Organization
Juntendo University Hospital
Division name
Department of Psychiatry
Zip code
Address
2-1-1. Hongo, Bunkyo-city, Tokyo 113-8421, Japan
TEL
03-3813-3111
ota@juntendo.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Tsuneyoshi Ota |
Organization
Juntendo University School of Medicine
Division name
Department of Psychiatry
Zip code
Address
2-1-1. Hongo, Bunkyo-city, Tokyo 113-8421, Japan
TEL
03-3813-3111
Homepage URL
ota@juntendo.ac.jp
Sponsor or person
Institute
Department of Psychiatry,
Juntendo University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 10 | Month | 25 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 09 | Month | 30 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 01 | Month | 01 | Day |
Last follow-up date
| 2014 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
| 2014 | Year | 03 | Month | 31 | Day |
Date trial data considered complete
| 2014 | Year | 03 | Month | 31 | Day |
Date analysis concluded
| 2014 | Year | 03 | Month | 31 | Day |
Other
Other related information
Management information
Registered date
| 2011 | Year | 10 | Month | 24 | Day |
Last modified on
| 2014 | Year | 10 | Month | 24 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007736
